United States Chronic Spontaneous Urticaria (CSU) Treatment Market 2025-2033: Rising Biologics and Novel Anti-Inflammatory Therapies | Sanofi S.A., Pfizer Inc., AstraZeneca

The Global Chronic Spontaneous Urticaria (SCU) Treatment Market reached US$ 719.94 Million in 2023, with a rise of US$ 778.40 Million in 2024 and is expected to reach US1,654.42 Million by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033.

This Chronic Spontaneous Urticaria (SCU) Treatment market addresses therapies for chronic hives without identifiable triggers. Rising incidence of autoimmune-related urticaria drives demand for effective treatments. Biologic drugs targeting IgE and histamine pathways are reshaping treatment protocols. Pharmaceutical R&D focuses on monoclonal antibodies and novel anti-inflammatory agents. Increasing awareness and diagnostic rates improve early intervention. The market continues to grow as biologics gain dominance in dermatological therapeutics.

📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Chronic Spontaneous Urticaria Treatment Market Landscape:- https://datamintelligence.com/download-sample/chronic-spontaneous-urticaria-treatment-market?rk

☛ Chronic Spontaneous Urticaria Treatment Market Recent Developments 2025:

United States:

✅ In July 2025, Horizon Therapeutics expanded access to its biologic therapy for CSU, improving symptom control and patient quality of life.

✅ In June 2025, Pfizer initiated Phase 3 trials for a new oral therapy targeting CSU patients unresponsive to antihistamines.

Japan:

✅ In August 2025, Torii Pharmaceutical launched an anti-IgE therapy for CSU, addressing growing demand in the Japanese population.

✅ In May 2025, Kyorin Pharmaceutical developed clinical protocols to integrate biologics with standard CSU care.

☛ Chronic Spontaneous Urticaria Treatment Market Trends:

This condition is treated with antihistamines, biologics, and immunomodulators. Market growth is driven by increasing prevalence, improved diagnosis, and emerging therapies.

Trends include biologics targeting IgE, personalized therapy, and guideline-based treatment optimization. North America dominates, while Europe and Asia-Pacific grow with awareness and healthcare access. Challenges include high treatment costs and chronic management.

☛ Chronic Spontaneous Urticaria Treatment Market Competitve Landscape:

Novartis AG, Genentech, Inc. (Roche Group), GlaxoSmithKline plc, Sanofi S.A., Pfizer Inc., AstraZeneca, Merck & Co., Inc., Teva Pharmaceuticals, Mylan N.V., and Sun Pharmaceutical Industries Ltd.

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/chronic-spontaneous-urticaria-treatment-market

☛ Segment Covered in the Chronic Spontaneous Urticaria Treatment Market:

By Treatment Type: H2-receptor Antagonists | Leukotriene Receptor Antagonists | Omalizumab (Monoclonal Antibodies) | Corticosteroids | Others

By Route of Administration: Oral | Injectable

By Distribution Channel: Hospital Pharmacies | Retail Pharmacies | Online Pharmacies

☛ This Report Includes:

✔ Comprehensive go-to-market strategies with actionable insights.

✔ Unbiased evaluation of overall market performance.

✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.

✔ Tailored regional and country-level reports with detailed localized analysis available on request.

✔ Identification of niche segments and high-growth regions presenting strong opportunities.

✔ Accurate regional forecasts using both top-down and bottom-up approaches.

📌 Get Corporate Access to Live Chronic Spontaneous Urticaria Treatment Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=chronic-spontaneous-urticaria-treatment-market

☛ Regional Analysis for Chronic Spontaneous Urticaria Treatment Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

☛ FAQ's

Q1: What is the current size of the Chronic Spontaneous Urticaria Treatment Market and its future potential?

A: Chronic Spontaneous Urticaria (SCU) Treatment Market reached US$ 719.94 Million in 2023, with a rise of US$ 778.40 Million in 2024 and is expected to reach US1,654.42 Million by 2033.

Q2: How fast is the Chronic Spontaneous Urticaria Treatment Market expected to grow in the coming years?

A: The market is forecast to expand at a robust CAGR of 8.8% between 2025 and 2032, signaling strong global growth and investment potential.

Q3: Which regions are dominating the Chronic Spontaneous Urticaria Treatment Market and which are fastest-growing?

A: North America dominating the Chronic Spontaneous Urticaria Treatment Market.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.